Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis

Leukemia. 2014 Dec;28(12):2273-5. doi: 10.1038/leu.2014.271.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Amyloidosis / drug therapy*
  • Amyloidosis / mortality
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Humans
  • Pyrazines / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib